Interestingly, a cost-effectiveness analysis conducted in patients with T1D undergoing AHSCT as compared to patients with T1D remaining on insulin therapy demonstrated that AHSCT provides some benefits over time depending on the duration of preserved glycated hemoglobin levels achieved with AHSCT, but overall being cost-effective for treatment of T1D if the AHSCT lasts from 3 to 8 years (38). This evidence concerns the gene INS and type 1 diabetes mellitus.